Access cutting-edge cholangiocarcinoma treatment through this phase 2 clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Seattle location
Preparing your pre-screening questions…
Access cholangiocarcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cholangiocarcinoma treatment provided free
Check if you qualify for this cholangiocarcinoma clinical trial in Seattle, WA
No-Cost Study Care
Local to Seattle
Convenient for WA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase II trial studies whether \[18F\]FTT can be used with positron emission tomography (PET)/computed tomography (CT) imaging to predict treatment response in patients scheduled to receive gemcitabine, cisplatin, and durvalumab (GCD) for newly diagnosed cholangiocarcinoma. PET/CT is an imaging technique that utilizes PET and CT in a single machine. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this trial, \[18F\]FTT, to make detailed, computerized pictures of areas inside the body where the tracer is used. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the patient's body. \[18F\]FTT targets and binds to poly (ADP-ribose) polymerase 1 (PARP1). Some cholangiocarcinoma tumor cells may express PARP1 which may make it easier to see them on PET/CT. Research has shown that tumor cells that express PARP1 may not respond well to GCD treatment. Researchers hope that by using \[18F\]FTT with PET/CT imaging they will be able to detect which patients have tumor cells that express PARP1, which may help predict treatment response in patients scheduled to receive GCD for newly diagnosed cholangiocarcinoma.
Sponsor: University of Washington
Yes, this clinical trial (NCT07673341) has an active research site in Seattle, WA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for cholangiocarcinoma treatment options in Seattle, WA, this clinical trial (NCT07673341) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced cholangiocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all cholangiocarcinoma clinical trials near you to find additional studies recruiting in your area.
See all liver cancer clinical trials recruiting in Seattle — not just this study.
Browse Liver Cancer Trials in Seattle →